1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
638B60C02FB03EA4D65257EBD00209BE5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/38B60C02FB03EA4D65257EBD00209BE5!OpenDocument
18
19OpenDocument
203.94.196.192
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Quality, Compliance and Regulatory Assuring Quality Programs

Document Excerpt: Benchmarking BioPharma Quality and CAPA Processes: Defining CAPA Benchmarks & Effectiveness Metrics

DB Image

ID: MD-477


Features:

9 Info Graphics

16 Data Graphics

100+ Metrics


Pages/Slides: 4


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click "
Download Free Excerpt".


To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5377 "Benchmarking BioPharma Quality and CAPA Processes: Defining CAPA Benchmarks & Effectiveness Metrics".


Industries Profiled:
Biotech; Pharmaceutical; Biopharmaceutical; Manufacturing; Health Care; Medical Device


Companies Profiled:
Amgen; AstraZeneca; Baxalta; Biogen; Douglas Pharmaceuticals; Eisai; Genzyme; GlaxoSmithKline ; ohm Laboratories; RIEMSER Pharma; Roche; UCB Pharma; United Therapeutics; Valeant


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.